Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
23rd December 2024 Uncategorised 0The FDA has approved Vertex’s Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis. But analysts have different views on how the switch from Vertex’s twice-daily Trikafta will play out.
More: Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
Source: fierce